Iwicki Mark T. - 14 Feb 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Chief Executive Officer, Director
Signature
/s/ Mark Iwicki
Issuer symbol
IKT
Transactions as of
14 Feb 2025
Net transactions value
$0
Form type
4
Filing time
19 Feb 2025, 20:26:03 UTC
Previous filing
07 Jan 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +4,373,857 $0.000000 4,373,857 14 Feb 2025 Common Stock 4,373,857 $2.35 Direct F1
transaction IKT Stock Option (Right to Buy) Award $0 +1,794,291 $0.000000 1,794,291 17 Feb 2025 Common Stock 1,794,291 $2.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 12, 2025, subject to the Reporting Person's continued employment through such date.